38 results about "Amiodarone" patented technology

The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parenteral administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared. Solutions can be made either dilutable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.

The present invention relates to a method for the treatment of atrial fibrillation comprising the coadministration of a synergistic therapeutically effective amount of amiodarone and synergistic therapeutically effective amount ranolazine. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated along with an anti-inflammatory agent into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period and minimize the inflammatory response. A particularly preferred drug is amiodarone and dexamethasone.

Methods and systems for treating patients suffering from or at risk of cardiac arrhythmias rely on the injection of amiodarone and other class III anti-arrhythmic drugs into the perivascular space surrounding a cardiac blood vessel. Injection may be achieved using intravascular catheters which advance needles radially outward from a blood vessel lumen or by transmyocardial injection from an epicardial surface of the heart.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

The invention provides a method for synthesizing an amiodarone impurity G and application of the amiodarone impurity G, and relates to the technical field of chemical synthesis. According to the method for synthesizing the amiodarone impurity G, the amiodarone impurity G can be synthesized by one-step reaction of 3-bromo-2-(1-methoxybutyl)benzofuran and 4-(2-(diethylamino)ethoxy)-3,5-diiodobenzoyl chloride which are adopted as raw materials under protection of inert gas. The method is easy to operate and low-cost, and has certain commercial value. In addition, when the amiodarone impurity G synthesized by the method is used as an impurity reference substance, a qualified, low-cost and readily-available reference substance is provided for quality control over amiodarone, and great guiding significance is provided for safe medication.

The invention encompasses ready to administer liquid formulations including amiodarone and a substituted cyclodextrin. The invention also encompasses methods of making the liquid formulations to provide acceptable concentrations of amiodarone suitable for parenteral administration. The liquid formulations of the invention are formulations included, for example, in a ready to use intravenous bag, bottle or syringe.

The invention encompasses ready to administer liquid formulations including amiodarone and a substituted cyclodextrin. The invention also encompasses methods of making the liquid formulations to provide acceptable concentrations of amiodarone suitable for parenteral administration. The liquid formulations of the invention are formulations included, for example, in a ready to use intravenous bag, bottle or syringe.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

The invention discloses a rat pulmonary cell fibrosis model. For a medication administration group, a medicine is administrated in an intranasal administration mode with an administration gun, the medicine comprises amiodarone and naphazoline hydrochloride, the amiodarone is adopted as an inducing agent for establishing the rat pulmonary cell fibrosis model, and the content of hdroxyproline is tested through high-resolution CT (Computed Tomography) observation. According to the rat pulmonary cell fibrosis model disclosed by the invention, the amiodarone is injected in a noninvasive intranasal administration mode to establish a lung fibrosis animal model, the operation is convenient, the success rate is high, small damage can be made to rats in the administration process, exogenous damage caused by tracheotomy of the rats is reduced, the death rate of the rats in the administration process is small, and medicines can be fed into tracheas completely.

Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus.

The presently disclosed subject matter provides a pharmaceutical composition and a method of treating Chagas disease. The pharmaceutical composition includes a dose of Itraconazole and a dose of Amiodarone and may be in the form of a liquid oral suspension. The liquid oral suspension may be produced through the use of pharmaceutically acceptable beads. In addition, the Itraconazole may be micronized to a small particle size before being formed into a composition with Amiodarone. The method for treating Chagas disease is effected by administering an effective amount of this pharmaceutical composition to a subject in need thereof, and the present composition is safer and more effective than previous compositions and with fewer undesirable side effects.

The invention discloses a drug screening model for treating arrhythmia diseases. The drug screening model comprises in vitro cardiac myocytes and a suspending medium, wherein the suspending medium is formed by NaCl, CaCl2, KCl, glucose, hydroxypropyl methyl cellulose, hydroxyethyl piperazinyl ethanesulfonic acid and water. The concentration of the NaCl is 3.7 mM-88.8 mM in the suspending medium; the concentration of the CaCl2 is 0.08 mM-1.8 mM in the suspending medium; the concentration of the KCl is 3 mM-12 mM in the suspending medium; the concentration of the glucose is 108.1 mM-246 mM in the suspending medium; the concentration of the hydroxypropyl methyl cellulose is 0.5 mM-0.54 mM in the suspending medium; and the concentration of the hydroxyethyl piperazinyl ethanesulfonic acid is 20 mM in the suspending medium. Through experimental evidence, the drug screening model of the invention can be used for screening out propafenone and amiodarone (which are both conventional drugs for treating the arrhythmia diseases). Therefore, the drug screening model of the invention has wide application prospect in the field of screening the drugs for treating heart-related diseases.

The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine.

The invention discloses a construction method and application of a spontaneous atrial fibrillation mouse model, and belongs to the technical field of atrial fibrillation animal models. According to the construction method, a whole-body DYNLT1 gene knockout mouse is constructed by using technologies such as gene editing and the like, the DYNLT1 gene knockout mouse is systematically evaluated through methods such as body surface electrocardiogram, echocardiography and histopathologic examination, and the DYNLT1 gene knockout mouse shows typical characteristics of atrial fibrillation in the aspects of body surface electrophysiology, atrial structure remodeling and the like. And in the molecular level, atrial muscle cell apoptosis is increased, gap junction protein expression is reduced, and inflammatory factor level is increased, so that the model is confirmed to be a spontaneous atrial fibrillation mouse model. In addition, the model shows a rapid drug reaction to the atrial fibrillation cardioversion drugs, such as amiodarone and propafenone, and has the potential for screening the atrial fibrillation drugs. The animal model provides a new pathological model for atrial fibrillation mechanism research and drug screening, and has important scientific research and clinical application values.

The invention relates to a plant extract for treating bradycardia, which is an oral preparation prepared from the extract of radix aconitilateralis preparata as the raw material, wherein the extract of radix aconitilateralis preparata is obtained by water extraction and alcohol deposition treatment. Pharmacodynamic tests and clinical practice of many kinds of chronic heart rate models prove that the extract can obviously raise the heart rate of bradycardia, and especially raise the heart rate of bradycardia caused by amiodarone. The total effective rate can reach more than 90%, the average heart rate increases 5-15 times / minute, the lasting period is long, and the extract can be repeatedly used without obvious adverse reaction.

The invention relates to a plant extract for treating bradycardia, which is an oral preparation prepared from the extract of radix aconitilateralis preparata as the raw material, wherein the extract of radix aconitilateralis preparata is obtained by water extraction and alcohol deposition treatment. Pharmacodynamic tests and clinical practice of many kinds of chronic heart rate models prove that the extract can obviously raise the heart rate of bradycardia, and especially raise the heart rate of bradycardia caused by amiodarone. The total effective rate can reach more than 90%, the average heart rate increases 5-15 times / minute, the lasting period is long, and the extract can be repeatedly used without obvious adverse reaction.

The invention discloses an automatic injection pump. The automatic injection pump comprises an injection pump body, wherein the injection pump body comprises a controller and a plurality of groups of actuating mechanisms and injectors, and the injectors are respectively filled with epinephrine, anti-ventricular fibrillation or pulseless ventricular tachycardia drug amiodarone and normal saline. The controller can control the actuating mechanisms to drive the epinephrine injectors to inject once every 3-5 minutes, can control the actuating mechanisms to drive the amiodarone injectors to inject, and can control the actuating mechanisms to drive the injectors filled with normal saline to inject once after medicine injection is completed every time. The automatic injection pump further comprises an operation panel, wherein an epinephrine starting button and an amiodarone starting button are arranged on the operation panel. According to the automatic injection pump, through automatic control of an automatic process, injection in a specified process can be accurately and automatically carried out or is manually carried out upon reminding, and rescue medicine can be well injected instead of manual operation; and meanwhile, the injection process can be automatically or manually started upon a reminding according to changes in vital signs of a patient.

The subject invention pertains to novel compounds (and salts thereof), and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns methods of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. This results in an improved safety profile. The new compounds have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The compounds also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

Amiodarone inhibits the invagination during zebrafish heart development and makes the defect on valves development. The present invention demonstrates that Amiodarone inhibits cancer metastasis and provides a method for inhibiting cancer metastasis in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of an Amiodarone or its salt.

The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by the parasite Trypanosoma cruzi known as Chagas disease. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Chagas disease, or in an amount effective to prevent Chagas disease in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The form of itraconazole used in the pharmaceutical composition may be prepared by any suitable process wherein the active ingredients to have sufficient bioavailability when injected into a human or animal subject. The long-term method for treating or preventing Chagas disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Chagas disease than previously possible.

The presently disclosed subject matter provides a method and pharmaceutical composition for long-term use in treating or preventing disease conditions caused by Leishmania species parasites such as Leishmaniasis. The pharmaceutical composition is a long-term injectable composition that can include a dose of Itraconazole and a dose of Amiodarone in an amount effective to treat Leishmaniasis, or in an amount effective to prevent Leishmaniasis in a human or animal patient such as a mammal. The pharmaceutical composition may also include a pharmaceutically acceptable vehicle, carrier, or excipient. The long-term method for treating or preventing Leishmania disease is carried out by a single injection of Itraconazole and Amiodarone in an amount effective to treat a subject in need thereof, and / or in an amount effective to prevent the subject from contracting the disease so that repeated dosages are not required again for a long-term period such as 6 or 12 months. The present compositions, methods, and uses are safer and longer lasting, more patient friendly, and provide a safer and more effective way of treating or preventing Leishmaniasis than previously possible.

Antifungal compounds having a benzofuran structure. Antifungals exhibit much less toxicity to human cells than amiodarone. These compounds are useful alone or in combination with other compounds having antifungal activity. Compounds of this invention exhibit synergistic antifungal activity in combination with antifungal amiodarone compounds. The invention provides pharmaceutical compositions useful for treating fungal infections, methods for treating fungal infections and compounds useful in such compositions for treating fungal infections. Compounds of this invention are further useful as antifungal agents for the prevention and or treatment of fungal infections in plants. The invention includes agriculturally useful compositions comprising one or more compounds of this invention which exhibit fungistatic or fungicidal function against one or more plant pathogen is a fungus.

The present invention provides a parenteral dosage form consisting essentially of a solution filled in a container, the solution comprising amiodarone or its pharmaceutically acceptable salt and a sulfo-alkyl ether beta-cyclodextrin in an aqueous vehicle, wherein the solution has a pH in the range of about 2.4 to 3.9 and further wherein the dosage form is sterilized by subjecting the filled container to autoclaving.